Opinion: Marty Makary misunderstood something fundamental about the FDA
Marty Makary resigned as FDA Commissioner after a tumultuous tenure marked by controversy and structural instability within the agency. His leadership was characterized by bypassing standard scientific processes, overruling career staff, and relying on non-traditional methods to announce policy changes. Critics argue that these actions undermined the FDA's credibility and decision-making integrity, despite some overdue reforms and well-intentioned initiatives.
- ▪Marty Makary resigned as FDA Commissioner amid widespread criticism of his management style and decision-making processes.
- ▪He and his deputy Vinay Prasad frequently overruled career scientists and relied on press releases instead of official vetted procedures to announce policy.
- ▪The Department of Government Efficiency dismissed thousands of career officials, weakening key agency functions and contributing to instability at the FDA.
- ▪Makary created a voucher program to expedite drug reviews, but some companies rejected it due to concerns about political interference.
- ▪Actions taken under Makary’s leadership, including the use of rubber-stamp advisory panels, raised concerns about the erosion of scientific integrity at the FDA.
STAT News files mainly under health. We currently carry 236 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT News |
| Canonical URL | https://www.statnews.com/2026/05/16/marty-makary-fda-commissioner-administrative-power/?utm_campaign=rss |
| Publication time | Sat, 16 May 2026 11:00:00 +0000 |
| Retrieval time | 2026-05-16T11:10:18.318Z |
| Last seen | 2026-05-16T11:10:18.318Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | T5E9IdoEDVF5 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
OpinionFirst Opinion Marty Makary misunderstood something fundamental about the FDA There is not, and never has been, a ‘deep state’ to shove aside Manage alerts for this article Email this article Share this article Marty Makary, flanked by NIH Director Jay Bhattacharya, left, and HHS Secretary Robert F. Kennedy Jr., speaks in the Oval Office last month.AP Photo/Julia Demaree Nikhinson By Joshua M. SharfsteinMay 16, 2026 Sharfstein served as principal deputy commissioner of the FDA from March 2009 to January 2011. On Tuesday, Food and Drug Administration Commissioner Marty Makary resigned from his position, leaving a vacancy at the top of the agency to match the turnover already challenging its drug and biologics divisions.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT News.
Discussion
0 commentsMore from STAT News
